CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Sotalol combines beta-blocking and class III antiarrhythmic properties. It prolongs the cardiac action potential by delaying repolarisation, which shows on the electrocardiogram as longer PR, QT and heart-rate-corrected QT (QTc) intervals (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of torsade de pointes with sotalol rises with the dose, a slow heart rate, low potassium and magnesium, high sotalol levels and use with other QT-prolonging drugs (AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone SmPC, AEMPS). The Spanish domperidone SmPC contraindicates such combinations because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation. It lists sotalol among the contraindicated class III antiarrhythmics (AEMPS). Sotalol does not bind to plasma proteins and is not metabolised. Of each dose, 80–90% leaves the body unchanged in urine (sotalol SmPC, AEMPS). The documents contain no data on sotalol changing domperidone levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Sotalol can cause torsade de pointes, usually after starting treatment or increasing the dose, but sometimes after long treatment without a dose change. Episodes may stop on their own or cause fainting, and in rare cases progress to ventricular fibrillation (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In clinical trials, 13% of people taking sotalol had a heart rate below 50 beats per minute (AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names sotalol among the class III antiarrhythmics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The original Spanish sotalol SmPC also contraindicates sotalol with QT-prolonging drugs and names domperidone among them. The US label says to avoid sotalol with such drugs (sotalol SmPC, AEMPS, and sotalol label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Start sotalol and increase its dose after an ECG with measurement of the heart-rate-corrected QT interval (QTc) and an assessment of kidney function, electrolytes and concomitant medicines, in a facility that can monitor heart rhythm (AEMPS). The US label says to hospitalise the patient for at least 3 days or until steady-state sotalol levels are reached, in a facility with cardiac resuscitation and continuous ECG monitoring (FDA). Correct low potassium or magnesium before starting sotalol (sotalol SmPC, AEMPS, and FDA label). If QRS or QT lengthens by 25% or more, PQ by 50% or more, or QTc exceeds 480 ms, reassess benefit and risk and seriously consider reducing the sotalol dose or stopping it (AEMPS). For torsade de pointes, the overdose section lists DC cardioversion, transvenous pacing, adrenaline or magnesium sulfate (sotalol SmPC, AEMPS). Stop domperidone if signs of arrhythmia appear (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Sotapor (sotalol) (nº registro 62001), sección 4.3 (2022)– AEMPS, CIMA, nº registro 62001, revisión 11/2022, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5